What is Chardan Capital’s Forecast for FDMT FY2025 Earnings?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at Chardan Capital issued their FY2025 earnings estimates for shares of 4D Molecular Therapeutics in a report issued on Monday, May 12th. Chardan Capital analyst Y. Livshits expects that the company will earn ($3.07) per share for the year. Chardan Capital currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

Several other research firms also recently weighed in on FDMT. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Barclays reduced their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. Royal Bank of Canada lowered their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group dropped their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, Bank of America decreased their target price on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $3.20 on Thursday. The stock’s 50-day moving average is $3.32 and its two-hundred day moving average is $5.15. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $28.93. The firm has a market cap of $148.24 million, a price-to-earnings ratio of -1.12 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02).

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after acquiring an additional 3,675 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in 4D Molecular Therapeutics by 139.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company’s stock valued at $364,000 after purchasing an additional 38,031 shares during the period. Proficio Capital Partners LLC boosted its holdings in 4D Molecular Therapeutics by 100.0% in the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $111,000 after purchasing an additional 10,000 shares in the last quarter. Vanguard Group Inc. increased its position in 4D Molecular Therapeutics by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock worth $15,933,000 after purchasing an additional 92,791 shares during the period. Finally, American Century Companies Inc. increased its position in 4D Molecular Therapeutics by 12.9% during the 4th quarter. American Century Companies Inc. now owns 38,785 shares of the company’s stock worth $216,000 after purchasing an additional 4,429 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.